Cargando…

Potential Utility of Novel Biomarkers in Active Surveillance of Low-Risk Prostate Cancer

Active surveillance (AS) is now an accepted management strategy for men with low-risk localized prostate cancer (PCa). However, detecting disease progression in a patient selected for AS remains a challenge. It is crucial to know what will serve as the best parameter to correctly identify tumors tha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Jeong Hyun, Hong, Sung Kyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4538404/ https://www.ncbi.nlm.nih.gov/pubmed/26339615 http://dx.doi.org/10.1155/2015/475920

Ejemplares similares

Clinical utility of current biomarkers for prostate cancer detection
por: Kim, Jeong Hyun, et al.
Publicado: (2021)

Analysis of expanded criteria to select candidates for active surveillance of low-risk prostate cancer
por: Jo, Jung Ki, et al.
Publicado: (2015)

Active surveillance for low-risk prostate cancer
por: Klotz, Laurence
Publicado: (2012)

Regional Variation in Active Surveillance for Low-Risk Prostate Cancer in the US
por: Washington, Samuel L., et al.
Publicado: (2020)

Early Experience With Active Surveillance in Low-Risk Prostate Cancer Treated
por: Ha, Ji Yong, et al.
Publicado: (2014)

Intraprostatic locations of tumor foci of higher grade missed by diagnostic prostate biopsy among potential candidates for active surveillance
por: Kim, Kwangmo, et al.
Publicado: (2016)

Super active surveillance for low-risk prostate cancer | Opinion: No
por: Ghodoussipour, Saum, et al.
Publicado: (2019)

Kallikreins as Biomarkers for Prostate Cancer
por: Hong, Sung Kyu
Publicado: (2014)

The role of 3-tesla diffusion-weighted magnetic resonance imaging in selecting prostate cancer patients for active surveillance
por: Jeong, Chang Wook, et al.
Publicado: (2014)

Active surveillance and focal therapy for low-intermediate risk prostate cancer
por: Klotz, Laurence
Publicado: (2015)

Super active surveillance for low-risk prostate cancer | Opinion: Yes
por: Reis, Leonardo O., et al.
Publicado: (2019)

The utility of prostate MRI within active surveillance: description of the evidence
por: Dominique, Georgina, et al.
Publicado: (2021)

Pathologic Outcomes in Men with Low-risk Prostate Cancer Who Are Potential Candidates for Contemporary, Active Surveillance Protocols
por: Kang, Ho Won, et al.
Publicado: (2015)

Active surveillance for low-risk prostate cancer – in pursuit of a standardized protocol
por: Sosnowski, Roman, et al.
Publicado: (2020)

Active surveillance for low-risk prostate cancer: well established, yet avoided?
por: Sosnowski, Roman, et al.
Publicado: (2022)

Patient and Context Factors in the Adoption of Active Surveillance for Low-Risk Prostate Cancer
por: Ciccone, Giovannino, et al.
Publicado: (2023)

Biomarker in Active Surveillance for Prostate Cancer: A Systematic Review
por: Manceau, Cécile, et al.
Publicado: (2021)

Socioeconomic determinants are associated with the utilization and outcomes of active surveillance or watchful waiting in favorable‐risk prostate cancer
por: Huang, Da, et al.
Publicado: (2023)

Trends in active surveillance for very low‐risk prostate cancer: do guidelines influence modern practice?
por: Parikh, Rahul R., et al.
Publicado: (2017)

Low-risk prostate cancer in India: Is active surveillance a valid treatment option?
por: Singh, Shanky, et al.
Publicado: (2020)

Understanding reasons for non-adherence to active surveillance for low-intermediate risk prostate cancer
por: Beckmann, Kerri, et al.
Publicado: (2021)

Active Surveillance for Intermediate Risk Prostate Cancer
por: Dall'Era, Marc A., et al.
Publicado: (2016)

Personalized schedules for surveillance of low‐risk prostate cancer patients
por: Tomer, Anirudh, et al.
Publicado: (2018)

Utilization of prostate brachytherapy for low risk prostate cancer: Is the decline overstated?
por: Safdieh, Joseph, et al.
Publicado: (2016)

Health state utilities among contemporary prostate cancer patients on active surveillance
por: Loeb, Stacy, et al.
Publicado: (2018)

Can microfocal prostate cancer be regarded as low-risk prostate cancer?
por: Lee, Seung Hwan, et al.
Publicado: (2013)

Prostate Cancer Imaging and Biomarkers Guiding Safe Selection of Active Surveillance
por: Glaser, Zachary A., et al.
Publicado: (2017)

Active Surveillance in Prostate Cancer: Role of Available Biomarkers in Daily Practice
por: Pastor-Navarro, Belén, et al.
Publicado: (2021)

Selection Criteria for Active Surveillance of Patients with Prostate Cancer in Korea: A Multicenter Analysis of Pathology after Radical Prostatectomy
por: Jeong, Chang Wook, et al.
Publicado: (2018)

Ongoing Debate on the Management of Small Renal Masses: Should They Be Treated Like Low-Risk Prostate Cancers?
por: Hong, Sung Kyu
Publicado: (2013)

A single-center long-term experience of active surveillance for prostate cancer: 15 years of follow-up
por: Song, Sang Hun, et al.
Publicado: (2021)

Frozen section utilization to omit systematic biopsy in diagnosing high risk prostate cancer
por: Tae, Jong Hyun, et al.
Publicado: (2022)

African American Men With Low-Risk Prostate Cancer Are Candidates for Active Surveillance: The Will-Rogers Effect?
por: Qi, Robert, et al.
Publicado: (2017)

Variation in the Use of Active Surveillance for Low-Risk Prostate Cancer Across US Census Regions
por: Al Hussein Al Awamlh, Bashir, et al.
Publicado: (2021)

Active surveillance versus nonradical treatment for low-risk men with prostate cancer: a review
por: Perera, Sachin, et al.
Publicado: (2022)

Time Trends and Variation in the Use of Active Surveillance for Management of Low-risk Prostate Cancer in the US
por: Cooperberg, Matthew R., et al.
Publicado: (2023)

Prediction of pathologic upgrading in Gleason score 3+4 prostate cancer: Who is a candidate for active surveillance?
por: Pham, Duc Minh, et al.
Publicado: (2020)

Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?
por: Beckmann, Kerri, et al.
Publicado: (2019)

Active surveillance in intermediate risk prostate cancer: is it safe?
por: Henk, G. van der Poel, et al.
Publicado: (2016)

Active surveillance in intermediate risk prostate cancer: is it safe?
por: Krishnananthan, Nishanth, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_s0o39cn9rf4cajp2mr99o2sjli